Hydrokortyzon Allefin (Hydrocortisone Acetate)

Hydrocortisone acetate penetrates the epidermis and binds to intracellular glucocorticoid receptors. This complex alters gene transcription, decreasing the production of inflammatory mediators like cytokines, prostaglandins and leukotrienes, which results in reduced inflammation and immune activity at the site of application.

The appropriate dose and frequency of Hydrokortyzon Allefin are determined by the prescribing healthcare professional based on the severity of the skin condition, patient age, and treatment area. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

Safety data for hydrocortisone acetate in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and import documentation.

Hydrokortyzon Allefin delivers hydrocortisone acetate, a low‑ to medium‑potency glucocorticoid. Compared with higher‑potency steroids such as betamethasone or clobetasol, it offers a milder anti‑inflammatory effect with a lower risk of skin atrophy, making it suitable for sensitive areas and long‑term use under medical supervision.

Store Hydrokortyzon Allefin at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Apply a thin layer of the topical preparation to the affected skin area as directed by the prescriber, usually 1–2 times daily. Gently massage until the product is absorbed, and wash hands before and after application unless the hands are the treatment site.

Serious risks include skin atrophy, hypopigmentation, systemic absorption leading to adrenal suppression, secondary infections, and rare allergic reactions such as anaphylaxis. Patients should report any severe skin changes, signs of infection, or systemic symptoms to their healthcare provider promptly.

Hydrokortyzon Allefin should be avoided in individuals with known hypersensitivity to hydrocortisone acetate or any formulation excipients, in patients with untreated fungal, bacterial or viral skin infections, and in those where systemic corticosteroid therapy is contraindicated without medical guidance.